

Kirsten Niebuhr-Ebel

From: Plaggenborg, Rainer <plaggenborg@GRUNECKER.DE>
Sent: 03 November 2016 10:05
To: Kirsten Niebuhr-Ebel
Cc: Zimmer, Franz-Josef; Rogers, Shelley
Subject: AW: EP14 781 729 (claim 1) - Our Ref.: EP101800FZRP

Dear Ms. Niebuhr-Ebel,

Thank you very much for the telephone conversation of yesterday.

Given that the claim is *structurally* limited by the full-length sequences of SEQ ID NOs: 4, 6, [...] 70, the *functional* definition described in the "wherein"-clause is not needed. Each of the sequences shows the claimed improvement (see Table 1). Accordingly, we would like to amend claim 1 as depicted in the following:

1. A variant biotin carboxyl carrier protein (BCCP) of SEQ ID NO: 2 comprising an amino acid substitution at position 2 of SEQ ID NO: 2, wherein said variant BCCP comprises a polypeptide sequence selected from the group consisting of SEQ ID NOS: 4, 6, 10, 14, 16, 20, 24, 32, 48, 70.

We look forward to hearing from you.

Best regards,
Rainer Plaggenborg

Dr. Rainer Plaggenborg
European Patent Attorney

GRÜNECKER
PATENT- UND RECHTSANWÄLTE

Leopoldstr. 4, 80802 Munich, Germany
Tel. +49 (0)89 21 23 50
Fax. +49 (0)89 22 02 87
plaggenborg@grunecker.de
www.grunecker.de

Grünecker Patent- und Rechtsanwälte PartG mbB
Amtsgericht München
Partnerschaftsregister 1397

CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGED COMMUNICATION

Note: This message is intended for the person/entity to whom it is addressed, and it contains privileged and confidential information. Should the reader not be the intended recipient, kindly notify us immediately by return e-mail or telefax and delete the original message and all copies thereof. Your cooperation is appreciated.

Von: Kirsten Niebuhr-Ebel [<mailto:kniebuhr@epo.org>]
Gesendet: Mittwoch, 2. November 2016 11:07
An: Plaggenborg, Rainer
Betreff: EP14 781 729 (claim 1)

1. A variant biotin carboxyl carrier protein (BCCP) comprising a **variant of the biotin carboxyl carrier protein (BCCP) of SEQ ID NO: 2 with an amino acid substitution at position 2 of SEQ ID NO: 2,**

wherein said variant BCCP comprises a polypeptide sequence selected from the group consisting of SEQ ID NOS: 4, 6, [...] 70, and wherein expression of said variant BCCP confers to a recombinant cell an increased production of a malonyl-CoA-derived compound when compared to a corresponding wild type cell.

Kirsten Niebuhr-Ebel
Examiner Directorate 1410
European Patent Office
Grasserstr. 9 | 80339 Munich | Germany
Tel. +49 (0)89 2399 7814
kniebuhr@epo.org
www.epo.org